Stay updated on ASG-22CE Dose Escalation in Nectin-4+ Tumors Clinical Trial
Sign up to get notified when there's something new on the ASG-22CE Dose Escalation in Nectin-4+ Tumors Clinical Trial page.

Latest updates to the ASG-22CE Dose Escalation in Nectin-4+ Tumors Clinical Trial page
- ChecktodayChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.6%
- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check22 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check51 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check65 days agoChange DetectedThe web page has undergone significant updates, including the removal of detailed study protocols and inclusion criteria for a clinical trial on enfortumab vedotin, while adding new collaborators and a revision number.SummaryDifference36%
- Check72 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to ASG-22CE Dose Escalation in Nectin-4+ Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ASG-22CE Dose Escalation in Nectin-4+ Tumors Clinical Trial page.